Elanco Animal Health Inc (ELAN) stock
Close on Nov 12, 2026Market cap $13.24BP/E –Yield –
Elanco Animal Health Inc grew revenue 12.1% to $5.15B over the twelve months to Sep 30, 2026. Free cash flow was $408.00M, up 10.9% from a year earlier. At the latest close the market valued the company at $13.24B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $13.24B
- P/E ratio
- –
- Price to sales
- 2.57
- Price to book
- 2.00
- Dividend yield
- –
- Free cash flow yield
- 3.08%
Fundamentals
- Revenue
- $5.15B
- Net income
- -$147.00M
- EPS, diluted
- -$0.31
- Free cash flow
- $408.00M
- Book value per share
- $13.09
- Diluted shares
- 507M
Trading
- Next earnings
- Feb 23, 2027 (estimated, before the open)
- Previous close
- $26.48
- Open
- $26.50
- Day's range
- $26.25 – $27.17
- Volume
- 4,315,069
- Average volume (20 days)
- 5,533,072
- Index membership
- S&P MidCap 400 (since Nov 2025), Russell 1000, Russell 3000
- Beta (5 years)
- 1.07
- 52-week range
- $19.40 – $27.98
- RSI (14 days)
- 66.5
- Volatility (1 year)
- 43.4%
- Relative volume
- 0.73×
- WACC
- 9.3%
Index membership is inferred from the holdings of funds that track each index (IJH, SPMD, IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2018, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | ELAN | S&P 500 | Difference | ELAN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +17.5% | -2.7% | +20.2 pts | ||
| 3 months | +19.7% | -1.7% | +21.5 pts | ||
| Year to date | +17.1% | +11.9% | +5.2 pts | ||
| 1 year | +20.2% | +12.0% | +8.2 pts | ||
| 3 years | +148.1% | +78.2% | +70.0 pts | +35.4% | +21.2% |
| 5 years | -19.8% | +73.2% | −93.0 pts | -4.3% | +11.6% |
| 10 years | +6694.9% | +309.6% | +6385.2 pts | +52.5% | +15.1% |
Eleven years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Net income
EPS, diluted
Free cash flow
Press releases
Releases Elanco Animal Health filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Update
- Update
About Elanco Animal Health
Pharmaceutical Preparations
Elanco Animal Health Incorporated develops, manufactures, and markets products to prevent and treat disease in pets and farm animals. Operating as a single segment within the animal health industry, the company provides treatments primarily for dogs, cats, cattle, poultry, swine, and sheep. Its product line encompasses parasiticides, dermatology treatments, vaccines, pain management therapeutics, medicated feed additives, injectable antibiotics, and enzymes. Elanco distributes its pet care offerings to third-party distributors, retailers, and veterinary clinics, while its farm animal products are supplied to commercial distributors and livestock producers.
Company profile, executives and historyElanco Animal Health stock: common questions
What is Elanco Animal Health's stock price?
ELAN closed at $26.50 on Nov 12, 2026, up 0.08% on the day. Over the past 52 weeks it traded between $19.40 and $27.98.
What is Elanco Animal Health's market cap?
Elanco Animal Health was worth $13.24B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is ELAN's P/E ratio?
Elanco Animal Health lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.31), so it has no meaningful P/E ratio.
How much revenue does Elanco Animal Health make?
Elanco Animal Health reported revenue of $5.15B for the twelve months to Sep 30, 2026, up 12.1% from a year earlier.
Does Elanco Animal Health pay a dividend?
No. Elanco Animal Health has not paid a cash dividend over the last twelve months.
When does Elanco Animal Health report earnings next?
Elanco Animal Health is expected to report Q4 FY2026 results on Feb 23, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has ELAN stock performed over the past year?
Including dividends, ELAN returned +20.2% over the past year, against +12.0% for the S&P 500.
How many ELAN shares are sold short?
33M shares were sold short at the latest FINRA report, 6.66% of the float, or 7.2 days of average trading volume.
Who are Elanco Animal Health's competitors?
Companies most similar to Elanco Animal Health by business, industry and size include ZTS, PAHC, OGN, AMRX, PRGO.
See a number that looks wrong?